Conceptual model of the course of chronic kidney disease (CKD).

Slides:



Advertisements
Similar presentations
Dietary Approach To C Kidney Disease
Advertisements

National service framework for Renal
The LIVES Sub-analysis
Volume 69, Issue 1, Pages (January 2006)
A.M. Thompson, T.G. Pickering  Kidney International 
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
Section 3: CKD, CVD and mortality
Volume 80, Issue 1, Pages (July 2011)
Volume 67, Pages S1-S7 (June 2005)
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
SAVE: Risk of total mortality associated with reduced kidney function
Volume 67, Issue 6, Pages (June 2005)
Volume 80, Issue 1, Pages (July 2011)
Differences in awareness, treatment, and control of hypertension between Southerners and non-Southerners Hypertension awareness, treatment, and control.
CKD: Common, Harmful, and Treatable—World Kidney Day 2007
Frederik Persson, Peter Rossing  Kidney International Supplements 
Nat. Rev. Nephrol. doi: /nrneph
Volume 83, Issue 3, Pages (March 2013)
Section 2: AKI Definition
Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline  Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,
Metabolic Complications in Elderly Adults With CKD
A Decade After the KDOQI CKD Guidelines
Melody Sherwood, Peter A McCullough  The Lancet Global Health 
John P. Middleton, Patrick H. Pun  Kidney International 
Chapter 3: Management of progression and complications of CKD
Chapter 5: Referral to specialists and models of care
Volume 72, Issue 10, Pages (November 2007)
Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
Volume 75, Issue 10, Pages (May 2009)
Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
Volume 70, Issue 11, Pages (December 2006)
Use of vitamin D in chronic kidney disease patients
Benefits of preserving residual renal function in peritoneal dialysis
H. Wong, K. Mylrea, J. Feber, A. Drukker, G. Filler 
American Journal of Kidney Diseases
Volume 73, Issue 12, Pages (June 2008)
Conceptual model of the natural history of diabetic kidney disease.
Evidence and Outcomes in CKD
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
Cardiovascular risk factors in chronic kidney disease
Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives  Keith A. Hruska, Suresh Mathew, Matthew.
Volume 64, Issue 2, Pages (August 2003)
Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.
Volume 72, Issue 3, Pages (August 2007)
Introduction: The case for updating and context
Volume 69, Issue 1, Pages (January 2006)
Association of HD treatment with polysomnographic parameters and EDS after adjustment for age, gender, and BMI. Error horizontal lines represent the 95%
Cardiovascular risk in chronic kidney disease
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.
Calcifications in autosomal dominant polycystic kidneys.
Volume 69, Issue 3, Pages (February 2006)
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Diagram of the mechanisms involved in limiting the ability of the kidney to maintain the levels of 1,25-dihydroxyvitamin D in chronic kidney disease (CKD).
Concurrent increase in African American (Af Am)/black hemodialysis population older than age 60 years between red bars (1986–2000). Concurrent increase.
The risk of siblings being affected depends on the mode of inheritance and the gender of the affected parent (in X-linked disease). The risk of siblings.
A loading dose decreases the time to achieve the target concentration.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.
Potential links between the immune dysfunction in uremia, inflammation, infection, and increased risk of atherosclerosis and cardiovascular disease. Potential.
Authors’ concept of aortic stiffness in relation to other cardiovascular risk factors. Authors’ concept of aortic stiffness in relation to other cardiovascular.
Risk for chronic kidney disease (CKD) among Olmsted County, MN, stone formers and control subjects. Risk for chronic kidney disease (CKD) among Olmsted.
Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.
Bias with estimated GFR (eGFR) by age (years).
Annual prevalence of proteinuria, hematuria, and combined proteinuria/hematuria on first screening in junior high school children in Tokyo, Japan between.
As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.
Grayscale ultrasonographic image in CKD
Perception of indications for referral to a nephrologist among internal medicine residents according to the postgraduate year (PGY). Perception of indications.
Presentation transcript:

Conceptual model of the course of chronic kidney disease (CKD). Conceptual model of the course of chronic kidney disease (CKD). Shaded ellipses represent stages of CKD; unshaded ellipses represent potential antecedents or consequences of CKD. Thick arrows between ellipses represent risk factors that are associated with the initiation and progression of disease that can be affected or detected by interventions: Susceptibility factors (black), initiation factors (dark gray), progression factors (medium and light gray), and end-stage factors (white). Interventions for each stage are given beneath the stage. People without CKD should be assessed for CKD risk factors. People who are known to be at increased risk for CKD should be tested for CKD. “Complications” refer to all complications of CKD and its treatment, including complications of decreased GFR (hypertension, anemia, malnutrition, and bone and mineral disease) and cardiovascular disease. Increasing thickness of arrows that connect later stages to complications represents the increased risk for complications as kidney disease progresses. Adapted from references (1–3), with permission. Andrew S. Levey et al. CJASN 2007;2:401-405 ©2007 by American Society of Nephrology